图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm(KPTI)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-001291 Act: 34 Size: 218 KB 网页链接
$Karyopharm(KPTI)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-021272 Act: 34 Size: 13 KB 网页链接
$Karyopharm(KPTI)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-013556 Act: 34 Size: 77 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-012832 Size: 4 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-012824 Size: 4 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007621 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007614 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007610 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007589 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007588 Size: 5 KB 网页链接